Peer-reviewed veterinary case report
Bioavailability of two oral L-thyroxine forms in healthy dogs
By Simpson, C et al.·Published in Australian veterinary journal·2013·Veterinary Hospital, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Bioavailability of two L-thyroxine formulations after oral administration to healthy dogs.
- Species:
- dog
Plain-English summary
A group of 11 healthy dogs was given two different forms of L-thyroxine, a medication used to treat thyroid problems. The dogs received either a liquid version or a tablet version, and their blood levels of the medication were measured over time. Both forms were found to be absorbed by the body similarly, with the tablet reaching a slightly higher concentration than the liquid. This means that either formulation can be effective for treating dogs with thyroid issues, depending on what the veterinarian recommends.
People also search for: dog thyroid medication options · L-thyroxine for dogs liquid vs tablet · dog thyroid treatment effectiveness
Abstract
OBJECTIVE: To describe the pharmacokinetics of two veterinary formulations of L-thyroxine available in Australia. METHODS: A two-phase randomised, crossover, open-label trial followed by a third-phase parallel-dosing trial was conducted in 11 healthy dogs with an investigative oral L-thyroxine liquid formulation and a reference tablet formulation. Blood sampling was done at defined intervals and serum total L-thyroxine concentrations were measured by radioimmunoassay. The post-dose concentrations were plotted as a function of time for each period and the relative bioavailability of the two formulations were compared using a general linear model with factors for dog, phase, sequence and formulation. RESULTS: Following oral administration of the reference tablet at the dose of 100 μg/kg, a maximum plasma concentration of approximately 96.2 nmol/L (baseline endogenous corrected) was reached within 3.77 h. For the investigative liquid preparation at a dose of 50 μg/kg, the maximum plasma concentration was 60.1 nmol/L (baseline endogenous corrected), which was reached within 3.59 h. CONCLUSION: The geometric mean of the relative bioavailability for the liquid/tablet product was 1.1, which suggests that the relative bioavailability of thyroxine following administration of tablet or liquid formulation is similar.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23438458/